• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Compugen Ltd.

    2/12/26 7:00:48 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEN alert in real time by email
    6-K 1 zk2634349.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of February 2026
    Commission File Number 000-30902

    COMPUGEN LTD.
    (Translation of registrant’s name into English)

    26 Harokmim Street
    Holon 5885849, Israel
    (Address of Principal Executive Offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40‑F:

    Form 20-F ☒  Form 40-F ☐ 
     


    Compugen Ltd.
     
    On February 12, 2026, Compugen Ltd. (the “Company”) issued a press release announcing the appointment of Michele Holcomb, Ph.D., as a new independent director, a copy of which is furnished as Exhibit 99.1 (the “Press Release”) to this Report on Form 6-K and incorporated by reference herein.
     
    Following her appointment, effective February 11, 2026, Dr. Michele Holcomb will hold office until immediately following the annual general meeting of the Company’s shareholders for 2026 and until her respective successor has been elected, or until her office is vacated earlier in accordance with the provisions of the Companies Law and the Articles.
     
    With the exception of the second, third, and fourth paragraphs in the Press Release, the information incorporated by reference, and included, in this Report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3, File No. 333-270985.

    Exhibit
     
    Number
    Description of Exhibit
     
     
    99.1
    Press Release dated February 12, 2026 – “Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors”



    Signatures

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     
    COMPUGEN LTD.
     
     
    Date: February 12, 2026
    By:
    /s/ Eran Ben Dor
     
     
     
    Eran Ben Dor
     
     
     
    General Counsel
     


    Get the next $CGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGEN

    DatePrice TargetRatingAnalyst
    4/7/2026$6.00Buy
    Lake Street
    1/7/2026$4.00Buy
    H.C. Wainwright
    1/13/2025$4.00Outperform
    Oppenheimer
    8/5/2022$2.00Buy → Hold
    Jefferies
    2/25/2022$17.00 → $14.00Outperform
    Oppenheimer
    2/25/2022$16.00 → $9.00Outperform
    SVB Leerink
    More analyst ratings

    $CGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Business Development Levine Zurit exercised 2,000 units of Ordinary Shares at a strike of $1.15 and sold $6,400 worth of Ordinary Shares (2,000 units at $3.20) as part of a pre-agreed trading plan (SEC Form 4)

    4 - COMPUGEN LTD (0001119774) (Issuer)

    4/27/26 4:03:18 PM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Ophir Eran exercised 5,000 units of Ordinary Shares at a strike of $0.83 and sold $16,000 worth of Ordinary Shares (5,000 units at $3.20) as part of a pre-agreed trading plan (SEC Form 4)

    4 - COMPUGEN LTD (0001119774) (Issuer)

    4/27/26 4:02:06 PM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Ophir Eran

    4 - COMPUGEN LTD (0001119774) (Issuer)

    4/15/26 4:10:27 PM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    SEC Filings

    View All

    SEC Form F-3 filed by Compugen Ltd.

    F-3 - COMPUGEN LTD (0001119774) (Filer)

    5/18/26 4:02:35 PM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Compugen Ltd.

    6-K - COMPUGEN LTD (0001119774) (Filer)

    5/18/26 7:00:20 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Compugen Ltd.

    144 - COMPUGEN LTD (0001119774) (Subject)

    4/13/26 7:28:42 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Compugen with a new price target

    Lake Street initiated coverage of Compugen with a rating of Buy and set a new price target of $6.00

    4/7/26 8:14:24 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Compugen with a new price target

    H.C. Wainwright initiated coverage of Compugen with a rating of Buy and set a new price target of $4.00

    1/7/26 9:09:29 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Compugen with a new price target

    Oppenheimer initiated coverage of Compugen with a rating of Outperform and set a new price target of $4.00

    1/13/25 8:13:52 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compugen Reports First Quarter 2026 Results

    COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026Gilead-partnered GS-0321 Phase 1 trial continues to progress as plannedSolid financial position with cash runway expected to fund operations into 2029HOLON, Israel, May 18, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunoth

    5/18/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum

    HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present at the 2026 Stifel Virtual Targeted Oncology Forum. The presentation will take place on Tuesday, May 19, 2026, at 10:00-10:25 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform

    5/12/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

    HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the foll

    5/4/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Financials

    Live finance-specific insights

    View All

    Compugen Reports First Quarter 2026 Results

    COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials and presented clinical and pre-clinical rilvegostomig data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer (DESTINY-Gastric03), with new data to be released at ASCO 2026Gilead-partnered GS-0321 Phase 1 trial continues to progress as plannedSolid financial position with cash runway expected to fund operations into 2029HOLON, Israel, May 18, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunoth

    5/18/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026

    HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its first quarter 2026 financial results on Monday, May 18, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, which is located at the foll

    5/4/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compugen Reports Fourth Quarter and Full Year 2025 Results

    Strengthened financial position through a non-dilutive transaction with AstraZeneca, monetizing a small portion of rilvegostomig royalties and extending expected cash runway into 2029Enhanced leadership team with Dr. Eran Ophir appointed President and CEO and Dr. Anat Cohen-Dayag transitioned to Executive ChairAdvanced clinical execution, including initiation of trials for wholly owned COM701 (MAIA-ovarian) and Gilead partnered GS-0321 and expansion of the Company's global clinical trial footprintPresented clinical updates for COM701 and GS-0321 at ESMO and SITC 2025, respectivelyOn track to have MAIA-ovarian interim analysis in Q1 2027Partner AstraZeneca reported promising Phase 2 rilvegost

    3/2/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

    SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

    2/10/23 10:30:03 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

    SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

    2/3/23 6:10:06 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Compugen Ltd. (Amendment)

    SC 13G/A - COMPUGEN LTD (0001119774) (Subject)

    2/9/22 2:26:16 PM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

    HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026. "On behalf of Compugen's Board of Directors, I am delighted to welcome Michele to the Board," said Anat Cohen-Dayag, Ph.D., Executive Chair, Compugen. "Michele brings more than three decades of experience spanning the biotech, pharmaceuticals and healthcare services industries. Her unique blend of strategic insights, corporate development, innovation and firsthand operation

    2/12/26 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

    Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

    2/18/25 8:00:00 AM ET
    $ALLT
    $BLRX
    $CGEN
    Computer Communications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compugen Appoints David Silberman as Chief Financial Officer

    HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio

    5/15/24 7:00:00 AM ET
    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care